Clinical Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate The Efficacy And Safety Of Sa237 As Monotherapy In Patients With Neuromyelitis Optica (Nmo) And Neuromyelitis Optica Spectrum Disorder (Nmosd).

Posted Date: Sep 15, 2016

  • Investigator: Aram Zabeti
  • Co-Investigator: Linda Lovell-Ewen
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

Neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) are disorders of the immune system which cause damage to nerve coverings. The purpose of this research study is to find out if SA237 is safe and effective in patients with NMO or NMOSD. SA237 i


You Are Being Asked To Take Part In This Research Study Because You Are 18 To 74 Years Of Age And You Have Been Diagnosed With Nmo Or Nmosd.


Neuromyelitis Optica Spectrum Disorder , Multiple Sclerosis, Nmo, Neuromyelitis Optica, Nmosd

For More Information:

Katie Krier

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.